Articles tagged with Breast Cancer
A new trial suggests that zoledronic acid may extend survival in postmenopausal breast cancer patients by boosting disease-free survival rates. However, the drug's effects on younger women are less clear-cut, with some studies indicating a possible adverse impact on recurrence rates outside bone.
A University of Melbourne study found that women with a strong family history of breast cancer but no genetic link are not consistently utilizing breast cancer services. They often struggle to interpret their risk and manage it effectively, leading to inadequate access to screenings and interventions.
A significant benefit of zoledronic acid was found for post-menopausal women with stage II/III breast cancer, with an overall survival rate of 85%. The drug may alter the balance of substances in the bone marrow micro-environment, potentially preventing cancer cells from spreading.
A 12-year update of the Breast International Group 1-98 trial shows that letrozole reduces the risk of breast cancer relapse by 18% and death by 21% compared to tamoxifen after surgery. The study provides long-term reassurance on the efficacy of aromatase inhibitors in preventing breast cancer recurrence.
A phase III clinical trial has shown that combining everolimus and exemestane significantly improves progression-free survival for women with advanced breast cancer resistant to hormonal therapy. The combination treatment resulted in an improved survival of nearly seven months compared to women treated with only exemestane.
Research reveals breast cancer tumors alter hormonal status and marker stability during relapse, impacting treatment decisions. Regular biopsies may be crucial in ensuring correct treatment and detecting other cancers or benign lesions.
A Phase II study showed that trastuzumab emtansine (T-DM1) significantly delayed breast cancer progression, improving patients' lives with fewer side effects. The treatment improved time to disease worsening by 41% compared to standard docetaxel chemotherapy plus trastuzumab.
A major UK trial found that giving radiotherapy between or during chemotherapy cycles significantly reduces the risk of breast cancer recurring in the breast or chest wall. The treatment, known as synchronous chemoradiation, has minimal adverse side-effects and no detrimental effect on quality of life.
A multi-institute team led by TGen will study triple-negative breast cancer, a highly aggressive form of the disease that disproportionately affects African-Americans. The research aims to uncover new ways of treating this aggressive form of breast cancer by understanding molecular makeup of breast cancer stem cells.
A study found that elderly breast cancer patients are more likely to die from age-related conditions rather than the disease itself, highlighting shortcomings in patient care. Researchers argue that these patients are being under-treated due to a false perception of their prognosis.
Researchers found that Adeno-associated virus type 2 (AAV2) targets all different grades of breast cancer by activating death pathways. The virus causes 100% of cancer cell destruction within seven days, with majority of cell death proteins activated on the fifth day.
Breast cancer researchers identify FGFR3 as a key protein responsible for tumor growth and resistance to hormone therapies. This discovery may lead to the development of novel drugs targeting this protein to treat recurrent breast cancers.
Researchers discovered that precancerous cells in high-risk African-American women consume high amounts of glucose and have activated insulin signaling pathways. Conditions like obesity and gestational diabetes can stimulate these cells, but exercise, weight loss, and metformin may help prevent aggressive breast cancer.
A study found that MRI screenings detected more breast cancer cases than mammography in high-risk, underserved women. The use of MRI also increased patient compliance with follow-up care. Lowering the cost of MRI may make this screening method more accessible to underinsured populations.
Three European medical oncologists, Johann de Bono, Rafael Rosell, and Hans Jörg Senn, have been recognized by ESMO for their groundbreaking work in prostate cancer management, lung cancer treatment, and breast cancer care. The awards celebrate their commitment to improving cancer research and clinical practice.
Researchers have identified a neurotransmitter released in response to stress that stimulates the growth and migration of breast cancer cells. The study found that this neurotransmitter, norepinephrine, and its receptor NPY play a key role in the progression of breast cancer.
Research reveals a strong association between stress and tumor aggressiveness in black and Hispanic breast cancer patients, compared to white patients. The study found that higher levels of psychosocial stress were linked to more aggressive tumors, suggesting potential impact on treatment outcomes.
Black women are more likely to develop a second breast cancer, even if they were not previously diagnosed with the disease. The average age for this development is significantly lower in black women compared to white women.
Researchers discovered that genes interact with each other in complex pathways, which can help breast cancer progress. Targeting multiple pathways may lead to more effective combination therapies against the disease. A diuretic used to treat hypertension also showed promise in stopping cancer cell progression.
A Spanish research establishes factors associated with tiredness in cancer survivors to improve their quality of life and rehabilitation. More than 66% of breast cancer survivors suffer from fatigue following recovery, caused directly by the disease, physical deterioration or treatment received.
A protein discovered by Dr. Suresh Alahari's laboratory can inhibit breast cancer cell growth and reduce tumor progression. The research found that Nischarin, a novel protein regulating breast cancer cell migration, acts as a tumor suppressor in breast cancer.
The study estimates 1.6 million new breast cancer cases and 425,000 new cervical cancer cases worldwide in 2010. Most cases occurred in developing countries, with a significant increase in women of reproductive age diagnosed with the diseases.
Breast and cervical cancer cases are rising globally, with more women dying at younger ages in developing countries. The study reveals stark differences in trends between high- and low-income countries, highlighting the need for increased cancer screening and treatment programs in poor nations.
Researchers at Helmholtz Association find that phytoestrogens, particularly lignans and their metabolite enterolactone, may help reduce breast cancer mortality. Enterolactone levels are linked to clinical disease progression and mortality risk, with higher levels associated with lower risk.
A study published in Food and Chemical Toxicology found that a soy-based natural S-equol supplement did not increase the risk of estrogen-sensitive breast cancer. The supplement, SE5-OH containing Natural S-equol, was previously shown to reduce menopause symptoms in postmenopausal women.
A web-based tool called WISE has been developed to help breast cancer survivors manage their symptoms and improve employment outcomes. The tool provides customized information and decision support tools to identify ergonomic workplace problems and implement changes.
Researchers developed a gene therapy that targets breast cancer stem cells, eliminating them and increasing chemotherapy effectiveness. The therapy, VISA-claudin4-BikDD, was shown to reduce tumor volume by 75% and extend survival in mice.
A new analysis found that women who inherit BRCA gene mutations develop breast and ovarian cancers at significantly younger ages than their female relatives in the previous generation. The study suggests that early age of diagnosis is crucial for providing effective counseling, screening, and treatment services.
A new study estimates that 27.6% of people will develop COPD by age 35, making it a significant public health concern. The risk is higher in men and those with lower socioeconomic status, emphasizing the need for increased awareness and funding to combat this chronic disease.
Researchers used computer-aided design to create accurate moulds and patient-specific physical scaffolds for breast tissue reconstruction. This technology holds promise for reducing scars, blood loss, and anaesthesia time, while improving surgical outcomes.
The Translational Genomics Research Institute (TGen) has been awarded $50,000 by the Inflammatory Breast Cancer Research Foundation to discover the genetic origins of Inflammatory Breast Cancer (IBC), a rare and aggressive form of breast cancer that rapidly progresses without warning.
A University of Maryland study found that young women with early-stage breast cancer who undergo lumpectomy and radiation have similar survival rates as those who undergo mastectomy. The analysis of nearly 15,000 patients showed no difference in overall or breast cancer-specific survival between the two groups.
Researchers have identified a mechanism that explains how cancer cells change their appearance and progress from a solid state to a semiliquid mass. The study found that microRNA-200S inactivation leads to this transformation, allowing tumour cells to evade natural defences and invade neighbouring organs.
Researchers discovered that certain BRCA1 mutations causing hyper-recombination contribute to breast and ovarian cancers by disrupting genomic stability. Targeted therapies may be developed by disrupting ubiquitination to prevent hyper-recombination and kill cancer cells.
A study published in Nutrition and Cancer found that a diet rich in walnuts can significantly reduce the risk of breast cancer in mice. The researchers discovered that the walnut-containing diet changed the activity of multiple genes relevant to breast cancer, leading to fewer tumors and smaller tumor sizes.
Researchers found that low-risk patients aged 60 or older with small tumors and low-grade disease have mortality rates comparable to the general population. These patients may not benefit from adjuvant therapy, contradicting previous recommendations for almost all patients with hormone-responsive disease.
A new study reveals that millions of dollars are raised annually for breast cancer research and prevention programs through revenue-generating initiatives. States with higher breast cancer death rates are more likely to offer specialty license plates, which generate significant revenue.
A collaborative study of African-American women's breast cancer will investigate genetic and non-genetic risk factors using a large population of 11,000 participants. The researchers aim to discover prevention methods for this deadly disease.
A decline in hormone therapy use among women aged 50-64 is linked to lower mammogram rates, as doctors may not remind them about upcoming mammograms. The study suggests that the drop in HT use led to a decrease in mammography rates between 2000 and 2005.
Researchers found that longer AI use was associated with increased heart disease and bone fractures, but lower rates of blood clots and womb cancer. Use of AIs for 2-3 years after initial treatment may explain the lack of overall survival benefit despite improved breast cancer recurrence
A phase 2 trial found that olaparib reduced tumor size in 41% of patients with ovarian cancer and no BRCA gene mutations. The treatment was generally well-tolerated and offered new hope for ovarian cancer treatment targeting DNA repair mechanisms.
A study by Boston University's Slone Epidemiology Center found that high parity was associated with a 50% increase in the incidence of estrogen-receptor negative (ER-) breast cancer, but only among women who had not breastfed. Breastfeeding was also linked to a reduced risk of ER- breast cancer, particularly in African-American women.
Abnormalities in breast cancer stem cells found in some cancers can lead to tumor development and recurrence, according to a recent study published by OHSU Knight Cancer Institute researchers. The study suggests that these mutated cells are resistant to chemotherapy and radiation, allowing the disease to recur.
Researchers found that breast tumor cells can evade NK cell antitumor activity by promoting self-tolerance. The study suggests that restoring NK cell function could benefit individuals with breast cancer.
A new study from Northwestern University finds that Chicago's south and southwest sides suffer the most in terms of residents' health and access to basic health resources. The study highlights significant disparities in healthcare access, including limited mammogram screening and HIV testing sites.
A study in mice found that a genetic variation in the CDKAL1 gene leads to misreading of insulin-producing genes, causing decreased insulin production and impaired cell function. Meanwhile, researchers discovered that breast cancer cells evade the antitumor activity of NK cells by modifying their environment.
Researchers at Georgetown University Medical Center found that overproduction of aromatase in breast tissue is more dangerous than excess estrogen receptors. Aromatase inhibitors may prove to be a more potent choice for cancer prevention in postmenopausal women.
Researchers found that NSAIDs inhibit COX-2, reducing tumor growth and metastasis. However, the safety of these drugs during pregnancy remains uncertain due to the complex changes occurring in the body after childbirth.
Researchers at Thomas Jefferson University discovered that blocking a receptor of a key hormone in the renin-angiotensin system reduces cancer cell growth by activating the enzyme AMPK, which inhibits fatty acid synthase. This finding suggests a potential target for chemopreventive agents to fight pancreatic cancer.
Women should have open discussions with their doctors about individualized breast cancer screening timing, considering personal preferences, risk factors, and understanding of mammogram benefits and harms. This is particularly important for women under 50, who may be subjected to false positives and unnecessary procedures.
A study found that trastuzumab increases the risk of heart problems in elderly women with a history of heart disease or diabetes. The researchers recommend referring these patients to a cardiologist and monitoring for cardiac function.
A study published in Genes & Development reveals a specific RNA cluster, miR-17~92, plays a key role in the growth of retinoblastoma, a rare form of childhood eye cancer. The researchers found that overexpression of this microRNA cluster helps cells proliferate despite the loss of tumor-suppressing protein Rb.
Researchers have identified new genetic markers for patients at high risk for bone metastasis, which may provide additional targets for preventing and treating the disease. A novel vaccine for HER2+ breast cancer is also being developed to address a particularly aggressive form of the disease.
Researchers present novel approaches to breast cancer treatment, including reconstituted cholesterol as a drug delivery model and heat-activated peptide therapy. These methods aim to improve patient outcomes by reducing side effects and increasing targeted treatments.
Research presented at the Era of Hope conference explores genes that contribute to breast cancer risk in African Americans and the possibility of mitigating it through vitamin D intake. Additionally, studies examine how daughters of BRCA mutation carriers manage their own risk of breast cancer.
A study found that a diet rich in omega 3 fatty acids and methyl nutrients may reduce the risk of breast cancer in female offspring. Researchers also discovered that supplementing a mother's diet with lipotropic nutrients during pregnancy may induce epigenetic changes, altering gene expression permanently.
Researchers found familial breast cancer patients have significantly shorter telomeres, suggesting a genetic mechanism contributing to disease progression. The study also demonstrated genetic anticipation in affected daughters, with decreased telomere length relative to their mothers.
Researchers at Lawson Health Research Institute have found that introducing maspin protein into the nucleus of cancer cells can significantly limit tumor growth and spread. This discovery may lead to new targets for drug development and improved understanding of cancer prognosis.
A UT Southwestern men's support group has published a book to reach out to husbands and partners of women with cancer. The book shares stories of five men who know firsthand what it's like to love and care for a cancer patient, offering emotional support and practical advice.
Using a 'systems biology' approach, researchers identified proteins in the blood that change in abundance long before aggressive breast cancer is clinically detectable. The study found that host tissues respond to and amplify signals from tumor cells, leading to changes in blood-protein levels.